ICY 주식 개요 바이오 제약 회사인 Incyte Corporation은 미국 및 전 세계에서 혈액학/종양학, 염증 및 자가 면역 분야의 치료제를 발견, 개발 및 상업화하는 데 관여하고 있습니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Incyte 과거 주가 현재 주가 US$64.00 52주 최고치 US$78.52 52주 최저치 US$47.11 베타 0.70 1개월 변경 -3.88% 3개월 변경 사항 7.45% 1년 변경 사항 14.65% 3년 변화 -0.71% 5년 변화 -19.41% IPO 이후 변화 303.07%
최근 뉴스 및 업데이트
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer Dec 08
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Nov 19
Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023) Oct 29
Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024 Oct 08
Insufficient new directors Oct 01 Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer 더 많은 업데이트 보기
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer Dec 08
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs Nov 19
Third quarter 2024 earnings released: EPS: US$0.55 (vs US$0.76 in 3Q 2023) Oct 29
Incyte Corporation to Report Q3, 2024 Results on Oct 29, 2024 Oct 08
Insufficient new directors Oct 01 Incyte 's Cdk2 Inhibitor Incb123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma Aug 16
Executive VP & Chief Medical Officer recently sold €644k worth of stock Aug 15
Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) Aug 15
Second quarter 2024 earnings released: US$2.04 loss per share (vs US$0.91 profit in 2Q 2023) Jul 31
Executive VP of Global Medical Affairs recently sold €1.0m worth of stock Jul 30
Incyte Corporation to Report Q2, 2024 Results on Jul 30, 2024 Jul 10
Executive VP & GM of North America recently sold €1.1m worth of stock Jun 16
Incyte Corporation (NasdaqGS:INCY) acquired Escient Pharmaceuticals, Inc. from a group of shareholders. Jun 01 Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares. May 16
Incyte Corporation (NasdaqGS:INCY) announces an Equity Buyback for $1,672 million worth of its shares. May 14
First quarter 2024 earnings released: EPS: US$0.76 (vs US$0.097 in 1Q 2023) May 01
Incyte Corporation, Annual General Meeting, Jun 12, 2024 May 01
Incyte Corporation Maintains Earnings Guidance for 2024 Apr 30
Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million. Apr 23
Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024 Apr 12
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS) Mar 11
Incyte Corporation Provides Earnings Guidance for 2024 Feb 14
Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022) Feb 13
Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024 Jan 24
Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease Dec 11
Incyte Corporation Provides Earning Guidance for the Full Year 2023 Nov 01
Third quarter 2023 earnings released: EPS: US$0.76 (vs US$0.51 in 3Q 2022) Oct 31 Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo Oct 12
Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023 Oct 11
Incyte Corporation Announces Executive Changes, Effective November 1, 2023 Sep 14
Executive VP & Chief Medical Officer recently sold €1.2m worth of stock Aug 06
Incyte Corporation Revises Earnings Guidance for the Year 2023 Aug 02
Second quarter 2023 earnings released: EPS: US$0.91 (vs US$0.73 in 2Q 2022) Aug 02
Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease Jul 25 Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023
Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023 May 09
First quarter 2023 earnings released: EPS: US$0.097 (vs US$0.17 in 1Q 2022) May 03
Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa Feb 11 Incyte Corporation Provides Earnings Guidance for the Year 2023
Full year 2022 earnings released: EPS: US$1.53 (vs US$4.30 in FY 2021) Feb 08
Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis Dec 13
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology Dec 06
Third quarter 2022 earnings released: EPS: US$0.51 (vs US$0.82 in 3Q 2021) Nov 02
Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine Oct 20
Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022 Oct 12
Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors Oct 05
Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion. Oct 04
Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement Aug 27
Second quarter 2022 earnings released: EPS: US$0.73 (vs US$0.68 in 2Q 2021) Aug 03
Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022 Aug 03
Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo Jul 19
Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022 Jul 13
FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata Jun 14
Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa) May 21
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 May 12
Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease May 05
First quarter 2022 earnings released: EPS: US$0.17 (vs US$0.24 in 1Q 2021) May 04
Incyte Corporation, Annual General Meeting, Jun 15, 2022 May 02
Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer Apr 23
Incyte Corporation to Report Q1, 2022 Results on May 03, 2022 Apr 13
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 09
Incyte Corporation Provides Revenue Guidance for the Full Year 2022 Feb 09
Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo Dec 15 MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020) Nov 03
Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million. Sep 29 Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD) Sep 23
Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults Sep 20
Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation Sep 19
Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Aug 25
Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial Aug 05
Second quarter 2021 earnings released: EPS US$0.68 (vs US$1.33 in 2Q 2020) Aug 04
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease Jul 15
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Jun 26
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis Jun 12
Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease Jun 09
Incyte and MorphoSys US, Inc. Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL Jun 05
Independent Director Paul Friedman has left the company Jun 05
Incyte Corporation Announces Positive Primary Analysis from the Phase 2 Optic Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (Cp-Cml) to Be Presented At the 2021 Asco Annual Meeting May 21
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo May 18
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma May 12
First quarter 2021 earnings released: EPS US$0.24 (vs US$3.33 loss in 1Q 2020) May 05
Incyte Corporation Provides Revenue Guidance for the Full Year 2021 May 05
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation Mar 19
Eli Lilly and Company and Incyte Announce Top-Line Results from BRAVE-AA2 Mar 04 주주 수익률 ICY DE Biotechs DE 마켓 7D -5.4% -2.9% -2.6% 1Y 14.7% -14.7% 6.9%
전체 주주 수익률 보기
수익률 대 산업: ICY 지난 1년 동안 -14.7 %를 반환한 German Biotechs 산업을 초과했습니다.
수익률 대 시장: ICY 지난 1년 동안 6.9 %를 반환한 German 시장을 초과했습니다.
가격 변동성 Is ICY's price volatile compared to industry and market? ICY volatility ICY Average Weekly Movement 5.8% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: ICY 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: ICY 의 주간 변동성 ( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 바이오 제약 회사인 인사이트 코퍼레이션은 미국 및 전 세계에서 혈액학/종양학, 염증 및 자가 면역 분야의 치료제를 발견, 개발 및 상업화하는 기업입니다. 이 회사는 중등도 또는 고위험 골수섬유증, 적혈구증가증, 스테로이드 불응성 급성 이식편대숙주질환 치료를 위한 자카피(성분명 룩소리티닙)를 제공합니다; 재발성 또는 불응성 미만성 거대 B세포 림프종 치료제 '몬주비'(타파시타맙-cxix)/민주비(타파시타맙), 액체 및 고형 종양 유형에서 발암 요인으로 작용하는 섬유아세포 성장인자 수용체 키나제 억제제 '페마자이어'(페미가티닙); 만성 골수성 백혈병 및 필라델피아 염색체 양성 급성 림프모구 백혈병 치료제 아이클루시그(포나티닙), 전이성 또는 재발성 국소 진행성 메르켈세포암 성인 치료제 자이닉스(레티판리맙-dlwr), 아토피 피부염 치료제 옵젤루라 크림 등이 있습니다. 임상 단계 제품으로는 항문관 편평상피세포암 및 비소세포폐암 치료제로 임상 3상 중인 레티판리맙, 만성 이식편대숙주질환 환자 치료제로 개발 중인 2상 항-CSF-1R 단일클론항체 악사틸리맙, 종양 발생 억제제 INCA033989, 질병 조절 치료제로 개발 중인 INCB160058, 고형암 치료용 INCB99280 및 INCB99318 등이 있습니다.
자세히 보기 Incyte Corporation 기본 사항 요약 Incyte 의 수익과 매출은 시가총액과 어떻게 비교하나요? ICY 기본 통계 시가총액 €12.38b 수익(TTM ) €31.13m 수익(TTM ) €3.91b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) ICY 손익 계산서(TTM ) 수익 US$4.08b 수익 비용 US$2.88b 총 이익 US$1.20b 기타 비용 US$1.16b 수익 US$32.48m
주당 순이익(EPS) 0.17 총 마진 29.33% 순이익 마진 0.80% 부채/자본 비율 0%
ICY 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/20 07:58 장 마감 주가 2024/12/20 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Incyte Corporation 55 애널리스트 중 23 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Jasper Hellweg Argus Research Company Thomas Russo Baird Ishan Majumdar Baptista Research
52 더 많은 분석가 보기 
